Search Within

Shanu Modi

  1. "Survivorship Research"
Formats
  1. Meeting Abstract (64)
  2. Journal Article (49)
Groups
  1. Breast Medicine Service (113)
  2. Department of Medicine (113)
  3. Solid Tumor Oncology Division (113)
  4. Survivorship Research (113)
  5. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (71)
  6. Epidemiology and Biostatistics (70)

More Groups

People
  1. Clifford Hudis (79)
  2. Larry Norton (50)
  3. Sujata Patil (43)
  4. Chau Dang (41)
  5. Sarat Chandarlapaty (36)
  6. Diana Lake (33)

More People

Years
  1. 2024 (7)
  2. 2023 (4)
  3. 2022 (5)
  4. 2021 (3)
  5. 2020 (7)
  6. 2019 (9)

More Years

Publications
  1. Journal of Clinical Oncology (31)
  2. Cancer Research (23)
  3. Breast Cancer Research and Treatment (11)
  4. Clinical Breast Cancer (7)
  5. Clinical Cancer Research (7)
  6. Annals of Oncology (5)

More Publications

Publishers
  1. American Association for Cancer Research (32)
  2. American Society of Clinical Oncology (32)
  3. Springer (11)
  4. Elsevier Inc. (9)
  5. Oxford University Press (8)
  6. American Medical Association (6)

More Publishers

Results (113)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase II study of gemcitabine (G), trastuzumab (H), and pertuzumab (P) for HER2-positive metastatic breast cancer (MBC) after prior pertuzumab-based therapy
    Meeting Abstract

    Iyengar, N. M.; Smyth, L. M.; Lake, D.; Gucalp, A.; Singh, J. C.; Traina, T. A.; DeFusco, P. A.; Dickler, M. N.; Fornier, M. N.; Goldfarb, S. B.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Phase II study of gemcitabine, trastuzumab, and pertuzumab for HER2-positive metastatic breast cancer after prior pertuzumab-based therapy
    Meeting Abstract

    Iyengar, N. M.; Smyth, L. M.; Lake, D.; Gucalp, A.; Singh, J. C.; Traina, T. A.; Defusco, P.; Dickler, M. N.; Fornier, M. N.; Goldfarb, S. B.; more...
    Annals of Oncology (2017)

    Fulltext@MSK | Save
  • A phase I trial of ganetespib in combination with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer
    Journal Article

    Jhaveri, K.; Wang, R.; Teplinsky, E.; Chandarlapaty, S.; Solit, D.; Cadoo, K.; Speyer, J.; D'Andrea, G.; Adams, S.; Patil, S.; more...
    Breast Cancer Research (2017)

    Fulltext@MSK | Save
  • Phase II study of gemcitabine, trastuzumab, and pertuzumab for HER2-Positive metastatic breast cancer after prior pertuzumab-based therapy
    Meeting Abstract

    Iyengar, N. M.; Smyth, L.; Lake, D.; Gucalp, A.; Singh, J. C.; Traina, T. A.; DeFusco, P.; Dickler, M. N.; Fornier, M. N.; Goldfarb, S.; more...
    Cancer Research (2017)

    Fulltext@MSK | Save
  • Pathologic complete response with neoadjuvant doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab and pertuzumab in patients with HER2-positive early stage breast cancer: A single center experience
    Journal Article

    Singh, J. C.; Mamtani, A.; Barrio, A.; Morrow, M.; Sugarman, S.; Jones, L. W.; Yu, A. F.; Argolo, D.; Smyth, L. M.; Modi, S.; more...
    The Oncologist (2017)

    Fulltext@MSK | Save
  • Phase II study of gemcitabine, trastuzumab, and pertuzumab for HER2-positive metastatic breast cancer after prior pertuzumab-based therapy
    Meeting Abstract

    Iyengar, N. M.; Smyth, L.; Lake, D.; Gucalp, A.; Singh, J.; Traina, T. A.; Defusco, P.; Dickler, M. N.; Fornier, M.; Goldfarb, S.; more...
    Annals of Oncology (2016)

    Fulltext@MSK | Save
  • The epichaperome is an integrated chaperome network that facilitates tumour survival
    Journal Article

    Rodina, A.; Wang, T.; Yan, P.; Gomes, E. D.; Dunphy, M. P. S.; Pillarsetty, N.; Koren, J. 3rd; Gerecitano, J. F.; Taldone, T.; Zong, H.; more...
    Nature (2016)

    Fulltext@MSK | Save
  • Biomarkers that predict sensitivity to heat shock protein 90 inhibitors
    Journal Article

    Jhaveri, K.; Chandarlapaty, S.; Iyengar, N.; Morris, P. G.; Corben, A. D.; Patil, S.; Akram, M.; Towers, R.; Sakr, R. A.; King, T. A.; more...
    Clinical Breast Cancer (2016)

    Fulltext@MSK | Save
  • Pathologic complete response rate with doxorubicin and cyclophosphamide followed by weekly paclitaxel with trastuzumab and pertuzumab in patients with HER2-positive early stage breast cancer: A single institution experience
    Meeting Abstract

    Singh, J. C.; Sugarman, S.; Jones, L.; Boafo, C.; Patil, S.; Schweber, S.; Yu, A.; Argolo, D.; Modi, S.; Iyengar, N.; more...
    Cancer Research (2016)

    Fulltext@MSK | Save
  • A phase I trial of ganetespib (heat shock protein 90 inhibitor) in combination with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor-2 positive (HER2+) metastatic breast cancer (MBC)
    Meeting Abstract

    Jhaveri, K.; Teplinsky, E.; Chandarlapaty, S.; Solit, D.; Cadoo, K.; Speyer, J.; D'Andrea, G.; Adams, S.; Patil, S.; Haque, S.; more...
    Cancer Research (2016)

    Fulltext@MSK | Save